Yu Ding
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Cancer Research top 10%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 9
- Cancer Immunotherapy and Biomarkers 7
- HER2/EGFR in Cancer Research 2
- Co-authors
- Vassiliki Karantza (5 shared papers)Peter Schmid (5 shared papers)David W. Cescon (3 shared papers)Deborah Toppmeyer (2 shared papers)Anne Armstrong (2 shared papers)Eric P. Winer (2 shared papers)Sylvia Adams (2 shared papers)Hiroji Iwata (2 shared papers)
- Journals
- Annals of Oncology (4 papers)Journal of Allergy and Clinical Immunology (3 papers)Journal of Clinical Oncology (2 papers)Cancer Research (2 papers)Med (1 paper)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Yu Ding
31 papers receiving 1.2k citations
Yu Ding's Hit Papers
Peers
Comparison fields: 5 of 87
- Oncology 581
- Cancer Research 217
- Immunology 253
- Pharmacology 112
- Pulmonary and Respiratory Medicine 189
Countries citing papers authored by Yu Ding
This map shows the geographic impact of Yu Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Ding more than expected).
Fields of papers citing papers by Yu Ding
This network shows the impact of papers produced by Yu Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Ding. The network helps show where Yu Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Yu Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 482 |
| 2 | 2000 | 111 | |
| 3 | 2021 | 87 | |
| 4 | 2023 | 76 | |
| 5 | 2017 | 55 | |
| 6 | 2019 | 53 | |
| 7 | 2000 | 46 | |
| 8 | 2016 | 42 | |
| 9 | 2012 | 35 | |
| 10 | 2018 | 27 | |
| 11 | 2020 | 26 | |
| 12 | 2023 | 23 | |
| 13 | 2013 | 18 | |
| 14 | 2021 | 16 | |
| 15 | 2014 | 13 | |
| 16 | 2020 | 12 | |
| 17 | 2020 | 8 | |
| 18 | 2020 | 8 | |
| 19 | 2019 | 8 | |
| 20 | 2014 | 8 |
About Yu Ding
Yu Ding is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Allergy and Surgery, having authored 35 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Allergic Rhinitis and Sensitization (6 papers), Breast Cancer Treatment Studies (3 papers), Esophageal Cancer Research and Treatment (3 papers), Asthma and respiratory diseases (3 papers), Advanced Breast Cancer Therapies (2 papers), Immune cells in cancer (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Oncology (581 citations), Cancer Research (217 citations), Immunology (253 citations), Pharmacology (112 citations) and Pulmonary and Respiratory Medicine (189 citations). Yu Ding has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Vassiliki Karantza, Peter Schmid, David W. Cescon, Deborah Toppmeyer, Anne Armstrong, Eric P. Winer, Sylvia Adams, Hiroji Iwata, Kenji Tamura and Pauline Wimberger. Their work appears in journals such as Annals of Oncology, Journal of Allergy and Clinical Immunology, Journal of Clinical Oncology, Cancer Research and Med.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.